Equasens (FRA:PHF) ROCE %: 19.43% (As of Dec. 2025)


FRA:PHF Equasens FRA:PHF
98 GF Score
Price €52.77
GF Value €85.09
! 2 Warning Signs
View Full Analysis

What is Equasens ROCE %?

Equasens FRA:PHF 98 ROCE % is 19.43% as of Dec. 2025. GuruFocus rates FRA:PHF with a GF Score™ of 98/100 and a GF Value™ of €85.09. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Equasens's annualized ROCE % for the quarter that ended in Dec. 2025 was 19.43%.

Equasens  (FRA:PHF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Equasens ROCE % Related Terms

Equasens ROCE % Historical Data

* Premium members only.

The historical data trend for Equasens's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Equasens ROCE % Chart

Equasens Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.29 22.54 21.57 16.55 16.94

Equasens Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.89 0.00 0.00 14.24 19.43
FRA:PHF
98GF Score
Equasens FRA:PHF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Equasens ROCE % Calculation

Equasens's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=52.439/( ( (398.012 - 101.565) + (438.986 - 116.39) )/ 2 )
=52.439/( (296.447+322.596)/ 2 )
=52.439/309.5215
=16.94 %

Equasens's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=62.678/( ( (0 - 0) + (438.986 - 116.39) )/ 1 )
=62.678/( ( 0 + 322.596 )/ 1 )
=62.678/322.596
=19.43 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 19.43% mean?
Equasens (FRA:PHF) has a ROCE % of 19.43% as of Dec. 2025.
Is Equasens' ROCE % too high?
Equasens' current ROCE % is 19.43%. The Healthcare Providers & Services industry median ROCE % is 6.41. Equasens' value of 19.43% is 203.1% above this industry median. Overall, Equasens has a GF Score™ of 98/100, reflecting its overall financial health beyond just this single metric.
How does Equasens' ROCE % compare to VEEV and BTSG?
Equasens' ROCE % of 19.43% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. Equasens' value of 19.43% is 203.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 648 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Equasens's current ROCE % of 19.43% is 203.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Equasens's current ROCE % is 19.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Equasens stock overvalued right now?
Equasens (FRA:PHF) has a current ROCE % of 19.43%. The stock's GF Value™ is €85.09, compared to a current price of €52.77 — trading 38% below its estimated fair value. The current ROCE % is 19.43% and 203.1% above the Healthcare Providers & Services industry median of 6.41. Equasens' overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Equasens (FRA:PHF), the current ROCE % is 19.43% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Equasens (FRA:PHF) Overvalued in 2026?

Based on GuruFocus' analysis, Equasens stock appears to be undervalued. The current stock price of €52.77 is trading 38% below its estimated GF Value™ of €85.09.

Key valuation signals for FRA:PHF:

  • ROCE %: 19.43%
  • GF Value™: €85.09 vs. price of €52.77 (38% below fair value)
  • GF Score™: 98/100 with 2 warning signs
  • Industry Position: 203.1% above the Healthcare Providers & Services median

No single metric tells the full story. See the FRA:PHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Equasens Business Description

Address 5 Allee de Saint-Cloud, Technopole de Nancy Brabois, Villers-les-Nancy, FRA, 54600
Equasens is engaged in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centers) and patients in both primary and secondary care sectors. The various activities that the company is involved in include: pharmacy software publishing and integration, publishing of IT solutions for health and medical/social establishments, and development of solutions and infrastructures for e-Health. With operations in France (its key revenue-generating market), Italy, Belgium, Germany, Ireland, and the United Kingdom, it is developing the healthcare platform and an ecosystem in France and Europe, benefiting people by making its technology services available.
98GF Score

Get the complete analysis for FRA:PHF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€52.77
Price
€85.09
GF Value